---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-065511"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:59:48.813966+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership

## Summary
- Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.
- Cash, cash equivalents and marketable securities $97.5M as of December 31, 2024.
- Closed $110M private placement in October 2024 (up to $275M if warrants exercised).
- Appointed Mark Iwicki CEO, Chris Cabell President & Head of R&D, John Adams CSO; added new board members.
- Received Study May Proceed letter for Phase 2b trial of IkT-001 in PAH in September 2024.

## SEC filing metadata
- accession: 0001193125-25-065511
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/0001193125-25-065511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/d943685d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-065511
- JSON: https://secwatch.observer/filing/0001193125-25-065511.json
- Plain text: https://secwatch.observer/filing/0001193125-25-065511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.